Mylan Investors Push Back At Bid To Toss EpiPen Claims
Investors in Mylan NV fired back at what they called a scattershot motion to dismiss their amended claims about alleged anti-competitive behavior involving the drugmaker's EpiPen epinephrine auto-injector, saying their latest...To view the full article, register now.
Already a subscriber? Click here to view full article